JD Health lifted operating profit 40.30 percent. JD Health stock sits 49.74 percent below target
Published on 10/13/2026 at 05:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- JD Health reported first-half 2026 revenue of CNY 40.90 billion, up 15.90 percent year over year.
- Non-IFRS operating profit rose 40.30 percent to CNY 3.50 billion, while the margin reached 8.50 percent.
- A CNY 61.76 consensus target stood 49.74 percent above the CNY 31.06 reference price on September 20, 2026.
- The last Lang & Schwarz quote was EUR 4.12 on October 12, 2026 at 10:57 p.m. CEST.
JD Health lifted first-half 2026 non-IFRS operating profit 40.30 percent to CNY 3.50 billion, while JD Health stock sat 49.74 percent below a CNY 61.76 target. GMT Eight reported on August 13, 2026 that revenue for the first half of 2026 reached CNY 40.90 billion, up 15.90 percent year over year.
Three dated operating signals
On August 13, 2026, JD Health released first-half results showing non-IFRS operating profit of CNY 3.50 billion and an operating margin of 8.50 percent, up from 7.00 percent. The combination of 15.90 percent revenue growth and 40.30 percent operating-profit growth points to faster profit expansion than sales.
On September 20, 2026, Eulerpool listed a 12-month consensus target of CNY 61.76 from 24 analyst ratings, alongside a CNY 31.06 reference price. The implied gap is 49.74 percent below the target when measured from that CNY 31.06 reference price.
On October 12, 2026, Sina Finance listed a JD Health clinic registration in Beijing with registered capital of CNY 5.00 million and reported a JD platform promotion offering products at 7.30 times ten percent of list prices. These dated developments extend the company story beyond online medicine sales into physical and promotional channels.
What does the margin increase change?
The margin move from 7.00 percent to 8.50 percent is a 1.50 percentage-point improvement in the first half of 2026. For investors, that difference matters because operating profit grew 40.30 percent while revenue grew 15.90 percent, creating a measurable profitability spread.
Next dates carry two milestones
Barrons lists December 2, 2026 for fourth-quarter 2026 earnings and March 29, 2027 for fiscal-year 2026 earnings for the Frankfurt-traded ADR. Those dates give the market two scheduled checkpoints for testing whether the first-half margin improvement continues.
Last euro quote is dated
JD Health was last at EUR 4.12 at Lang & Schwarz on October 12, 2026 at 10:57 p.m. CEST. The quote is dated before the publication date, so the article uses it as the last available euro price rather than as a current trading-day move. The further course of trading is shown by the continuously updated real-time quote of JD Health stock.
JD Health stock key data
- Company: JD Health International Inc.
- ISIN: KYG5074A1004
- Ticker: 6618.HK
- Primary exchange: HKEX
- Last price Lang & Schwarz (as of October 12, 2026, 10:57 p.m. CEST): EUR 4.12
- Sector / Industry: Healthcare / Medical - Pharmaceuticals
Market context: Market report Latest market reports.
